Today: 29 June 2026
UnitedHealth Falls Premarket as Berkshire Sells Stake
18 May 2026
2 mins read

UnitedHealth Falls Premarket as Berkshire Sells Stake

New York, May 18, 2026, 04:03 EDT

• UnitedHealth slipped 4.8% to $375.06 in early premarket trade, after finishing Friday at $393.85. StockAnalysis
• Berkshire Hathaway said it dumped its UnitedHealth holding in a first-quarter shuffle. Reuters
• These moves landed ahead of the NYSE regular session, which opens at 9:30 a.m. and closes at 4:00 p.m. Eastern.

UnitedHealth Group shares slid early Monday in premarket trading as Berkshire Hathaway’s exit from the stock put new pressure on a recent rally for the health insurer.

Shares were set at $375.06 in premarket trading at 4:00 a.m. EDT, about 4.8% below Friday’s close of $393.85. The stock was already off 1.3% on Friday, as the S&P 500, Nasdaq, and Dow each finished in the red.

Timing is a factor here. UnitedHealth was coming off a run toward a 52-week high as investors got interested in managed-care stocks again. The stock closed Friday up 25.4% over the last 30 days, just 2.6% under its May 13 high of $404.15.

Berkshire disclosed on Friday that it dumped a handful of smaller positions, with UnitedHealth, Amazon, Visa and Mastercard all sold. Reuters said the moves came as part of a broad first-quarter shakeup following Greg Abel’s CEO appointment. Berkshire’s U.S. stocks made up nearly all of its $288 billion portfolio at the end of March.

UnitedHealth’s operations are not affected by the sale, but the move could dampen sentiment. Selling tied to Buffett sometimes grabs attention, as investors watch Berkshire’s portfolio shifts for signals, even if it’s not clear from the filing which manager was behind a trade.

UnitedHealth’s bounce lately is tied to medical costs coming in lower than feared. Major U.S. health insurers like UnitedHealth, Cigna, Humana and Elevance Health all posted first-quarter beats, with several saying they had better control over expenses, Reuters reported last week. Medical costs are what insurers pay for patient care. If they rise quicker than premiums, margins get squeezed.

UnitedHealth posted first-quarter revenue of $111.7 billion, a 2% rise, with adjusted earnings at $7.23 per share. The company lifted its 2026 adjusted earnings forecast to above $18.25 per share. CEO Stephen Hemsley said UnitedHealth aims to deliver “greater value, affordability, transparency and connectivity” in health care. unitedhealthgroup.com

Strong start but caution for UnitedHealth this year, CFO says

UnitedHealth’s management isn’t calling the pressure off yet. Speaking at the BofA healthcare conference, CFO Wayne DeVeydt said Q1 was strong, but stressed the need to watch April and May since a lot of Q1 claims get paid then. If the first-quarter trends keep going, DeVeydt said, “this will be a very strong year.” StockAnalysis

Analysts are saying pretty much the same thing. “It is probably a little early to call a victory,” Morningstar analyst Julie Utterback told Reuters. Whit Mayo at Leerink Partners said claims tend to surprise health insurers in the second quarter, making it “the test” for most. Reuters

Cost relief may not last. Flu was mild and weather may have slowed care use early in the year. Medicare Advantage is still stuck with payment rates that don’t always match real costs. UnitedHealthcare CEO Tim Noel told the BofA crowd that some benefit cuts in 2027 are probably on the table to help margins.

Humana is seen as more exposed to Medicare Advantage, and Elevance is being looked at for signs on commercial and government-plan spending. Investors will be watching peers to see if the same read-through holds. If these companies show a solid second quarter, that bolsters the bull case. But a spike in claims would put more weight on Friday’s Berkshire disclosure.

UnitedHealth heads into Monday trading with a rebound in earnings on one side and the recent exit of a big shareholder on the other. The opening auction will be the stock’s first test.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Fast-Growing Australian Stocks With High Insider Ownership: Telix Pharmaceuticals and Lindian Resources
    June 28, 2026, 9:57 PM EDT. Investors seek fast-growing Australian stocks with high insider ownership for aligned incentives and growth potential. Telix Pharmaceuticals (ASX:TLX), valued at A$5.20 billion, develops radiopharmaceuticals targeting cancer diagnosis and treatment, supported by collaborations and active clinical trials despite recent stock declines and regulatory scrutiny. Lindian Resources (ASX:LIN), worth A$1.68 billion, focuses on rare earths and minerals projects in Africa and Australia, with analysts projecting growth. These stocks offer exposure to innovation and sector-specific catalysts amid varying market conditions including persistent inflation and easing bond yields.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
QuantumScape Stock Ends Volatile Week Down; Bulls Still Looking for Key Catalyst
Previous Story

QuantumScape Stock Ends Volatile Week Down; Bulls Still Looking for Key Catalyst

GCT Semiconductor jumps in premarket trade with traders looking at 5G move
Next Story

GCT Semiconductor jumps in premarket trade with traders looking at 5G move

Go toTop